Clinical response across the board is more likely with the Respond CRT SystemTM, whatever the patients’ baseline conditions.1
Responder rate, odds ratio and interaction P value for subgroups*
*P values <0.15 were considered significant for interaction
In particular, results showed a 22% absolute higher response for patients with AF history and a 16% absolute higher response for patients with renal dysfunction.
The chart below shows the difference in responder rates for subgroups
SonR lead to a 47% risk reduction in Cardiovascular Death or Hospitalization for patients with AF history.2
SonR lead to a 40% risk reduction in Cardiovascular Death or Hospitalization for patients with renal dysfunction.2
1. Brugada J, Delnoy P.P, Brachmann J, Reynolds D, Padeletti L, Noelker G, Kantipudi C et al. 2016. “Contractility sensor-guided optimization of cardiac resynchronization therapy: results from the RESPOND-CRT trial.” European Heart Journal 38 (10): 730-738. doi:10.1093/eurheartj/ehw526.
2. LivaNova data on file. Presented by J Brugada – Late Breaking Trial – ESC 2016
Where do we stand after two decades of trying to find the right CRT optimization strategy? Experts discuss the results of the RESPOND-CRT trial and the implications for clinical practice.
SonR technology is available exclusively in LivaNova devices. Learn more about the Platinium SonR™ family of CRT-D devices.
This site is intended for healthcare professionals outside the United States of America. By continuing to use this site you are confirming that that you are a healthcare professional based outside the USA.
